Financial Performance - Total revenue increased 13% year-over-year to $60.2 million, with telehealth revenue growing 18% to $47.3 million[6] - Adjusted EBITDA rose 20% to $5.1 million, while telehealth adjusted EBITDA increased 30% to $2.9 million[6] - For the fourth quarter of 2025, the company expects revenue in the range of $45 million to $46 million and adjusted EBITDA between $3 million and $4 million[10] - Full year 2025 revenue is projected to be between $192 million and $193 million, reflecting an increase of approximately 24% versus 2024[10] - Total revenues for the nine months ended September 30, 2025, increased to $186.98 million, a 25.3% rise from $149.34 million in the same period of 2024[20] - Gross profit for Q3 2025 was $52.76 million, compared to $48.26 million in Q3 2024, reflecting an increase of 9.3%[20] - The consolidated adjusted EBITDA for the nine months ended September 30, 2025, was $19,796,724, significantly higher than $8,115,725 for the same period in 2024[28] Subscriber Growth - The number of active telehealth subscribers increased 14% to approximately 310,000 at quarter-end[9] - LifeMD's RexMD business added nearly 10,000 net new subscribers in the quarter, returning to growth[3] Debt and Cash Management - LifeMD paid off all outstanding debt during the quarter, significantly strengthening its balance sheet[5] - Cash at the end of Q3 2025 was $23.79 million, down from $37.59 million at the end of Q3 2024[22] - Net cash used in operating activities for Q3 2025 was $(147,137), a significant decrease from $6.20 million provided in Q3 2024[22] Operating Loss and Expenses - Operating loss for Q3 2025 narrowed to $(1.97) million, an improvement from $(4.00) million in Q3 2024[20] - Net loss attributable to LifeMD, Inc. for Q3 2025 was $(3.81) million, compared to $(4.66) million in Q3 2024, showing a reduction of 18.2%[20] - Total expenses for the nine months ended September 30, 2025, were $164.94 million, up from $149.13 million in the same period of 2024[20] Telehealth Performance - Telehealth revenue for Q3 2025 reached $47.28 million, up 17.5% from $40.15 million in Q3 2024[20] - Telehealth operating loss for the three months ended September 30, 2025, was $3,043,374, an improvement from a loss of $3,745,522 in 2024[29] - Telehealth adjusted EBITDA for the nine months ended September 30, 2025, reached $10,494,043, compared to $2,664,501 in 2024[29] WorkSimpli Performance - LifeMD completed the divestiture of its majority ownership in WorkSimpli, transforming into a pure-play virtual care and pharmacy platform[4] - WorkSimpli reported an operating income of $1,074,160 for the three months ended September 30, 2025, a recovery from an operating loss of $250,752 in 2024[30] - WorkSimpli adjusted EBITDA for the nine months ended September 30, 2025, was $9,302,680, up from $5,451,224 in 2024[30] Other Financial Metrics - Gross margin was 88% compared to 91% in the prior-year period, with telehealth gross margin at 86% excluding WorkSimpli[9] - The company incurred litigation costs of $959,802 for the three months ended September 30, 2025, compared to $644,170 in 2024[29] - Stock-based compensation expense for the three months ended September 30, 2025, was $3,198,036, compared to $2,394,235 in 2024[29] - The company reported a foreign exchange loss of $314,960 for the three months ended September 30, 2025[30] - Interest expense (excluding amortization of debt discount) for the nine months ended September 30, 2025, was $1,317,389, compared to $1,266,412 in 2024[28] Strategic Plans - LifeMD plans to enhance its core telehealth business while managing the non-core subsidiary WorkSimpli separately[24]
LIFEMD(LFMDP) - 2025 Q3 - Quarterly Results